该技术没有限制,可以适应各种癌症。 在全球范围内,300 项 CAR-T 细胞疗法的临床试验已获得欧洲、美国、以色列、中国和澳大利亚的药物监管机构的批准。 India plans cell therapy treatment for cancer Indian pharmaceutical companies and start-ups may so...
CAR-T在实体瘤研究中仅占比20%,但针对实体瘤的 CAR-T 越来越多地涉及难以治疗的癌症,包括胃癌和胰腺癌。 Tecelra的成功无疑会为CAR-T的实体瘤研究提供宝贵的借鉴和思路,相信针对实体瘤的CAR-T疗法批准即将到来。 Ref. Fidler, B. First-of-its-ki...
Gilead Sciences with two approved CAR-T therapies, Yescarta® and Tecartus®, reported total revenues of USD 1,459 million in FY 2022 from the sales of its CAR-T therapies. For the company, nearly 66% of the cell therapy sales are generated in the US. ...
近五年来,肿瘤免疫治疗的药物和手段也显现出爆炸性的增长,包括CTLA-4,PD-1和PD-L1等T细胞检查点抑制剂[2],新抗原疫苗,融瘤病毒,以及细胞治疗(包括CAR-T,T细胞共激活因子,白细胞介素)等等;此外,肿瘤免疫治疗还有各种各样的联合疗法。 这里最具有戏剧性的发展是最近被美国食品药品管理局(FDA)批准的治疗难治复发...
These living drugs have taken the research community by storm, and the US Food and Drug Administration has approved several CAR-T cell therapies for blood cancers such aslymphomasand multiplemyeloma. But scientists are still struggling to work out whether these cells can be used to kill ‘solid...
A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell LymphomasWells, Drew A.Summerlin, JennaHalford, ZacheryJournal of Hematology Oncology Pharmacy
the FDA modified the REMS for several approved CAR-T therapies, removing requirements for educational and training materials as well as the requirement to report adverse events suggestive of CRS or neurological toxicities. According to Autolus, marketing authorization applications for o...
INSTACAR™, our integrated platform supporting CAR-T innovation INSTACAR™ is ICT’s proprietary platform that enables key service capabilities essential for advancing personalized cellular therapies, including cryopreservation, immunotherapy research and development, medical diagnostics, and scientific researc...
Impressive progress has been made in the treatment of hematological malignancies, translated in the FDA approval of several CD19 CAR T therapies [3,4,5,6]. However, considerable challenges still remain for use of CAR T cell therapy to treat solid tumors, preventing them of being approved for...
19. Leick MB, et al. Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies Mol Ther 2021; 29(2):433-441. 20.Leila A, et al. Preparing for CAR-T cell therapy: patient selection, bridging ther...